mad1

Mad1 (6-21) is a peptide fragment derived from the Mad1 protein, specifically encompassing residues 6 to 21. This fragment exhibits binding affinity towards the mammalian Sin3A PAH2 domain, with a Kd value of approximately 29 nM.

Mad1 (6-21) TFA, a fragment encompassing amino acids 6 to 21 of the Mad1 protein, exhibits a strong affinity for the PAH2 domain of mammalian Sin3A with a dissociation constant (Kd) of approximately 29 nM [1].

ML347 (LDN 193719)(DN193719) is a highly specific ALK1/2 inhibitor ( IC50: 46/32 nM), and the selectivity for ALK2 is >300-fold than ALK3.

Astragaloside II (Astrasieversianin VIII) is an effective MDR reversal agent and may be a potential adjunctive agent for hepatic cancer chemotherapy. Astragaloside II also induces osteogenic activities, differentiation, proliferation, and mineralization, through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.

Zilurgisertib fumarate (INB-000928 fumarate) is a potent and selective inhibitor of Activin Receptor-Like Kinase 2 (ALK2/ACVR1). It significantly inhibits ALK2 kinase activity (IC50 = 15 nM) and downregulates BMP-6-induced SMAD1/5 phosphorylation (IC50 = 63 nM). By blocking ALK2-mediated signaling, Zilurgisertib suppresses the production of hepcidin in hepatocytes (IC50 = 20 nM), thereby modulating iron metabolism. In preclinical studies, Zilurgisertib demonstrates the potential to improve anemia in cancer-induced models by effectively increasing hemoglobin levels.

Dalbergioidin exhibits tyrosinase inhibitory activity with an IC50 of 20 mM. It shows a melanin biosynthesis inhibition zone in the culture plate of Streptomyces bikiniensis that has commonly been used as an indicator organism. Dalbergioidin protects MC3T3-E1 osteoblastic cells against H2O2-induced cell damage through activation of the PI3K/AKT/SMAD1 pathway, suggests that it may be useful in bone metabolism diseases, particularly osteoporosis. Dalbergioidin also ameliorates doxorubicin-induced renal fibrosis by suppressing the TGF-β signal pathway.